Carlin Barnes
Child & Adolescent Psychiatry · Houston, TXNPI 1730190562
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,272 of the $6,577 with a category attached, or 80.1%. 24 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 24.6% of the total. 2025 is the largest year on record at $3,012, 3.2 times the $951 reported in 2019. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $31.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- Johnson & Johnson$1K
- Supernus Pharmaceuticals, Inc.$504
- Takeda Pharmaceuticals U.S.A., Inc.$465
- Teva Pharmaceuticals USA, Inc.$451
- Otsuka America Pharmaceutical, Inc.$330
- plus $2K from 18 others
What the payments were for
- Travel & lodging$1,08316%
- Food & beverage$5,27280%
- Education$2233%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 17 | $1,618 |
| Johnson & Johnson | 42 | $1,292 |
| Supernus Pharmaceuticals, Inc. | 45 | $504 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $465 |
| Teva Pharmaceuticals USA, Inc. | 7 | $451 |
| Otsuka America Pharmaceutical, Inc. | 16 | $330 |
| Tris Pharma Inc | 10 | $294 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $184 |
| Sunovion Pharmaceuticals Inc. | 14 | $183 |
| Alkermes, Inc. | 2 | $138 |
| Neos Therapeutics, LP | 2 | $135 |
| E.r. Squibb & Sons, L.L.C. | 2 | $128 |
| Lundbeck LLC | 5 | $125 |
| AbbVie | 4 | $111 |
| Axsome Therapeutics, Inc. | 1 | $109 |
| Sage Therapeutics, LLC | 1 | $107 |
| Shire North American Group Inc | 4 | $95 |
| Gilead | 1 | $88 |
| Ironshore Pharmaceuticals Inc. | 3 | $73 |
| Adlon Therapeutics L.p. | 3 | $60 |
| Neuronetics, Inc. | 2 | $37 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Corium, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$440
- INVEGA$150
- INVEGA SUSTENNA$132
- INVEGA TRINZA$132
- QELBREE$130
- Dyanavel XR$124
- Austedo XR$122
- SPRAVATO$121
- Adzenys XR-ODT$117
- Cotempla XR-ODT$117
- TRINTELLIX$115
- Auvelity$109
- INGREZZA$106
How this compares
$6,577 in reported general payments places this provider in the 90th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 62 | $2,858 |
| Aripiprazole | 23 | $810 |
| Bupropion XlBupropion Hcl | 14 | $568 |
| Lamotrigine | 11 | $209 |
| Alprazolam | 25 | $174 |
| Zolpidem Tartrate | 23 | $171 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Houston
- Sonam BhaktaHouston$7K
- Jay TarnowHouston$6K
- Kay LewisHouston$6K
- Ann Menendez-CaldwellHouston$6K
- Sriramamurthy RavipatiHouston$4K
- Cesar Soutullo EsperonHouston$3K
- Peter WuHouston$3K
- Monica GroverHouston$3K
- Charles MorelandHouston$3K
- Zargham AbbasHouston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.